Aoife Brennan
Amministratore Delegato presso ELIEM THERAPEUTICS, INC.
Patrimonio netto: 46 671 $ in data 31/05/2024
Profilo
Aoife M.
Brennan is currently the President, Chief Executive Officer & Director at Eliem Therapeutics, Inc. She is also a Director at FibroGen, Inc., Cerevance, Inc., and Xilio Therapeutics, Inc. Additionally, she serves as an Advisor at Atlas Venture Advisors, Inc. Previously, Dr. Brennan held the position of President, Chief Executive Officer & Director at Synlogic, Inc. from 2016 to 2024.
She was also the Director-Clinical Development at Tolerx, Inc. from 2008 to 2011.
From 2018 to 2020, she served as an Independent Director at Ra Pharmaceuticals, Inc. Prior to that, she was the Vice President & Head-Rare Disease Innovation Unit at Biogen, Inc. from 2011 to 2016.
She also held the role of Chief Medical Officer at Synlogic Operating Co., Inc. from 2016 to 2018.
Dr. Brennan obtained a doctorate degree from Trinity College Dublin and a graduate degree from Harvard Medical School in 2008.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
FIBROGEN, INC.
0.02% | 05/06/2024 | 19 658 ( 0.02% ) | 23 590 $ | 31/05/2024 |
SYNLOGIC INC
0.13% | 31/03/2024 | 14 796 ( 0.13% ) | 23 082 $ | 31/05/2024 |
Posizioni attive di Aoife Brennan
| Società | Posizione | Inizio |
|---|---|---|
| FIBROGEN, INC. | Direttore/Membro del Consiglio | 05/08/2020 |
| XILIO THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 13/06/2024 |
| ELIEM THERAPEUTICS, INC. | Amministratore Delegato | 27/06/2024 |
Cerevance, Inc.
 Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Direttore/Membro del Consiglio | 01/01/2020 |
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Consulente / Consigliere | - |
Precedenti posizioni note di Aoife Brennan
| Società | Posizione | Fine |
|---|---|---|
| SYNLOGIC, INC. | Amministratore Delegato | 09/03/2024 |
| RA PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 02/04/2020 |
| BIOGEN INC. | Corporate Officer/Principal | 01/08/2016 |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Corporate Officer/Principal | 01/04/2011 |
| ░░░░░░░░ ░░░░░░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░░░ | - |
Formazione di Aoife Brennan
| Trinity College Dublin | Doctorate Degree |
| Harvard Medical School | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| SYNLOGIC, INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| FIBROGEN, INC. | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| ELIEM THERAPEUTICS, INC. | Health Technology |
| Aziende private | 5 |
|---|---|
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Synlogic Operating Co., Inc.
 Synlogic Operating Co., Inc. Pharmaceuticals: MajorHealth Technology Synlogic Operating Co., Inc. operates as a biopharmaceutical company. The firm's pipeline focuses on rare diseases, the company is leveraging the broad potential of its synthetic biotics platform for novel drug development in major disease areas through partnerships with pharmaceutical and biotechnology companies. It also engages in development of synthetic biotics-based treatment for inflammatory bowel disease. The company was founded by James J. Collins and Timothy K. Lu in 2014 and is headquartered in Cambridge, MA. | Health Technology |
Cerevance, Inc.
Cerevance, Inc. Medical SpecialtiesHealth Technology Cerevance, Inc. provides pharmaceutical services. The firm discovers new treatments for central nervous system diseases. Its platform enables to profile specific brain cell types including both neurons and glial cells in mature human brain tissue. The company was founded by Bradley A. Margus and Mark Carlton in 2016 and is headquartered in Boston, MA. | Health Technology |
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
- Borsa valori
- Insiders
- Aoife Brennan
